- Home
- REFI vs TSHA Comparison
REFI vs TSHA Comparison
Compare REFI & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | TSHA |
|---|---|---|
| Founded | 2021 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 1.2B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | REFI | TSHA |
|---|---|---|
| Price | $13.46 | $5.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $20.00 | $10.22 |
| AVG Volume (30 Days) | 99.6K | ★ 3.4M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 15.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $54,287,847.00 | $6,310,000.00 |
| Revenue This Year | $13.78 | N/A |
| Revenue Next Year | $4.07 | N/A |
| P/E Ratio | $7.95 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.85 | $1.05 |
| 52 Week High | $16.29 | $5.95 |
Technical Indicators
Market Signals| Indicator | REFI | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 66.72 | 67.47 |
| Support Level | $12.60 | $5.22 |
| Resistance Level | $12.92 | $5.54 |
| Average True Range (ATR) | 0.25 | 0.32 |
| MACD | 0.10 | 0.15 |
| Stochastic Oscillator | 97.22 | 92.43 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.